Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Value of Functional Fascicular Block in Patients With Atrioventricular Re-Entrant Tachycardia.

JACC. Clinical electrophysiology·2025
Same author

Flecainide for the Treatment of Andersen-Tawil Syndrome.

JACC. Clinical electrophysiology·2025
Same author

Loss of right ventricular capture: When it is not the lead's fault.

HeartRhythm case reports·2025
Same author

Acute alcohol exposure and electrocardiographic changes: Finding from the HOLIDAY trial.

Journal of electrocardiology·2024
Same author

Palpitations and Recurrent Syncope in a Young Woman.

Circulation·2024
Same author

Comparison of non-laser and laser transvenous lead extraction: a systematic review and meta-analysis.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2023
Same journal

Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The future of cardiovascular training: Bridging global disparities and building a hybrid model for equity in care.

Current problems in cardiology·2026
Same journal

Disparities in healthcare access and treatment outcomes for patients with chronic limb-threatening ischemia.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Optimizing cardiac resynchronization therapy for congestive heart failure.

Srikant Duggirala, Byron K Lee

    Current Problems in Cardiology
    |May 14, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Cardiac resynchronization therapy (CRT) improves outcomes for heart failure patients. Optimizing CRT involves advanced imaging and device programming to maximize biventricular pacing and reduce mechanical dyssynchrony for better results.

    More Related Videos

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    Related Experiment Videos

    Last Updated: May 11, 2026

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
    12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    Area of Science:

    • Cardiology
    • Biomedical Engineering

    Background:

    • Advanced systolic heart failure often presents with mechanical dyssynchrony.
    • Cardiac resynchronization therapy (CRT) is a key treatment for these patients, improving symptoms and survival.
    • Optimizing CRT delivery is crucial for maximizing patient benefit.

    Purpose of the Study:

    • To review current approaches for optimizing cardiac resynchronization therapy (CRT).
    • To highlight the role of imaging and device programming in enhancing CRT efficacy.
    • To discuss methods for reducing cardiac dyssynchrony through tailored CRT.

    Main Methods:

    • Review of existing literature on CRT optimization techniques.
    • Analysis of imaging modalities for identifying optimal lead placement (e.g., latest mechanical activation).
    • Evaluation of device programming strategies, including atrioventricular and interventricular interval adjustments.

    Main Results:

    • Imaging can guide left ventricular lead implantation to the region of latest mechanical activation.
    • Device programming, particularly optimizing biventricular pacing and intervals, can significantly reduce dyssynchrony.
    • Tailored CRT approaches demonstrably enhance therapeutic benefits in heart failure patients.

    Conclusions:

    • Optimizing CRT through advanced imaging and precise device programming is essential.
    • Targeting mechanical dyssynchrony with CRT leads to improved clinical outcomes.
    • Further refinement of CRT techniques promises to maximize its effectiveness in systolic heart failure.